Publicado
Rosuvastatin: role in cardioascular high-risk patient
Rosuvastatin: Role in Cardiovascular High-risk Patient
Palabras clave:
Hydroxymethylglutaryl-CoA Reductase Inhibitors, cardiovascular diseases, dyslipidemias, Cost-Effectiveness Evaluation (en)Inhibidores de Hidroximetilglutaril-CoA Reductasas, enfermedades ardiovasculares, dislipidemias, evaluación de Costo-Efectividad (es)
Referencias
Russell DW. Cholesterol biosynthesis and metabolism. Cardiovascular Drugs Therap. 1992; 6:103-10.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-3421.
Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. For the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39.
Hayward RA, Krumholz HM. Three reasons to abandon low density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes. 2012; 5:2-5.
Rubba P, Marotta G, Gentile M. Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Management. 2009; 5:343-52.
McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscl Suppl 2003; 4:9-14.
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. For the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003; 92:152-60.
Jones P, Kafonek S, Laurora I, Hunninghake D. For the CURVES Study Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol. 1998; 81:582-7.
Nicholls SJ, Brandrup-Wongsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy ot increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010; 105:69-76.
Mackie BD, Satija S, Nell C, Miller J. 3rd Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol. 2007; 15:291.
Joy T, Hegele RA. Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients. Can J Cardiol. 2009; 25:453.
Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, et al. Effectiveness and tolerability of every-otherday rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008; 42:341-6.
Li JJ, Yang P, Liu J, Jia YJ, Li ZC, Guo YL, et al. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clin Chim Acta. 2012; 413:139-142.
Dulay D, LaHaye SA, Lahey KA, Day AG. Efficacy of alternate day versus daily dosing of rosuvastatin. Can J Cardiol. 2009; 25:e28-31.
Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Stroke. 2002; 33:2337-41.
Astra Zeneca Pharmaceuticals. Crestor® (rosuvastatin calcium) tablets prescribing information. Wilmington, DE. 2005.
Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risk of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol. 2008; 102:1654-62.
Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJMed. 2012; 105:145-57.
Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007; 29:253-60.
García-Rodríguez LA, Herings R, Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparting rosuvastatin with other marketed statins. Pharmacoepidemiol Drug Saf. 2010; 19:1218-24.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statins trials. Lancet. 2010; 375:735-42.
Disponible en: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Acceso 28 de febrero de 2012.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. For the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285:1711-8.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. Intensive versus Moderate Lipid Loweringwith Statins after Acute Coronary Syndromes. N Engl J Med. 2004; 350:1495-1504.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention ofcardiovascular events and death with pravastatin in patients with coronary heart disease and abroad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol loweringwith simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002; 360:7-22.
ASCOT Study group: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomizedtrial. Lancet. 2003; 361:1149-58.
Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease(PROSPER): a randomised controlled trial. Lancet. 2002; 360:1623-30.
Colhoun HM, Betteridge J, Durrington PN, Neil HA, Hitman GA, Livinstone SJ, et al. Primary prevention of Cardiovascular disease in type 2diabetes in the Collaborative Aorvastatin Diabetes Study (CARDS): multicentre ramdomised placebo controlledtrial. Lancet. 2004; 364:685-96.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl JMed. 1995; 333:1301-7.
Downs JR, Clearfield M, Weis S, Withney E, Shapiro DR, Beere PA, et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998; 279:1615-22.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, et al. For the JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N Engl J Med 2008; 359:2105-2207.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T,Peto R, Collins R, Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials. Lancet. 2008; 371:117-125.
Mills EJ, Wu P. Chong G, Ghement I, Singh S, Akl EA. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJMed 2011; 104:109-124.
Sadowitz B, Maier KG, Gathan V. Statin therapy part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010; 44:241-51.
Hall AS, Jackson BM, Fairin AJ, Efthymiou M, Barth JH, Copeland J, et al. On behalf of the SPACE ROCKET Trial Group. A randomized, controlled trial os simvastatin vs rosuvastatin in patients with acute myocardial inraction: the secondary prevention of acute coronary events-reduction of cholesterol to key European targets trial. Eur J Cardiovasc Prev Rehabil. 2009; 16:712-21.
Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipidmodifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR Study). Am J Cardiol 2012; 109:1239-46.
Clearfield MB, Amerena J, Bassand JP, Hernández-García HR, Miller SS, Sosef FFM, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia- Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006; 7:35.
Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low density lipoprotein cholesterol and non high density lipoprotein cholesterol targets in high risk patients. The MERCURY II (Measuring Effective Reduction in Cholesterol Using Rosuvastatin therapy II) trial. J Am Coll Cardiol. 2008; 52:626-32.
Leiter LA, Rosenson RS, Stein E, Reckless J, Schulte KL, Schleman M, et al. On behalf of the POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg vs atorvastatin 80 mg in high risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194:e154-e164.
Bots AFE, Kastelein JJP. Achieving lipid goals in real life: the Dutch DISCOVERY Study. Int J Clin Pract. 2005; 59:1387-94.
Strandberg TE, Feely J, Sigurdsson EL. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY study. Clin Ther. 2004; 26:1821-33.
Zhu JR, Tomlinson B, Young MR, Sim KH, Lee LT, Sriratanasathavorn C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study) Curr Med Res Opin. 2007; 23:3055-3068.
Binbrek AS, Elis A, Al-Zaibag M, Eha J, Keber I, Cuevas AM, et al. For the DISCOVERY Alpha Study Group Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha Study) Curr Ther Res. 2006; 67:21-43.
Herregods MC, Daubresse JC, Michel G, Lamotte M, Vissers E, Vandenhoven G. DISCOVERY BELUX: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. Acta Cardiol. 2008; 64:493-9.
Laks T, Keba E, Leiner M, Merilind E, Petersen M, Reinmets S, et al. Achieving lipids goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open label, parallel group, multicenter study: the DISCOVERY Beta study. Vasc Health Risk Manag. 2008; 4:1407-16.
Gupta M, Constance C. Direct statin comparison of LDL-C values: an evaluation of rosuvastatin therapy (DISCOVERY - Canada). [abstract] Atheroscler Suppl. 2005; 6:108.
Fonseca FAH, Ruiz A, Silva JM, Fuenmayor M, Marotti M. For the DISCOVERY PENTA Investigators. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value - an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin. 2005; 21:1307-15.
Middleton A, Fuat A. Achieving lipid goals in real life: the DISCOVERY-UK study. Br J Cardiol. 2006; 13:72-6.
Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, et al. On behalf of the ECLIPSE study investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia. Cardiology 2008; 111:219-28.
Costa-Scharplatz M, Ramanathan K, Frial T, Beaner B, Gandhi S. Cost effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin and pravastatin from a Canadian Health System perspective. Clin Ther. 2008; 30:1345-57.
Tian YBL, Frial T, Miller PSJ. Statin´s cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol 2007; 14:e205-14.
Miller PSJ, Smith DG, Jones P. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein goals compared with atorvastatin, pravastatin and simvastatin (a US analysis of the STELLAR trial). Am J Cardiol. 2005; 95:1314-9.
Hirsch M, O´Donell J, Olsson A. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int J Cardiol 2005; 104:251-6.
Huse DM, Russel MN, Miller JD, Kraemer DF, D´Agostino RB, Ellison RC, et al. Cost effectiveness of statins. Am J Cardiol 1998; 82:1357-63.
Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patients characteristics. Ann Intern Med. 2000; 132:769-79.
Huse DM, Song X, Ozminkowski RJ, Maguire J, William SA, Borok GM, et al. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US Managed Care and Medicare populations: a data analysis. Clin Ther. 2006; 28:1425-42.
Gandhi SK, Jensen WM, Foz KM, Somolen L, Olsson AG, Paulsson T. Cost-effectiveness of rosuvastatin in comparison wuth generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. Clinico Economics Outc Res. 2012; 4:1-11.
Visitas a la página del resumen del artículo
Descargas
Cómo citar
Licencia
Derechos de autor 2013 Revista de la Facultad de Medicina
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-
